Letetresgene autoleucel

Phase 2Cell therapy

GSK

Letetresgene autoleucel is one of 30 small molecule programs targeting Neoplasms. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

NeoplasmsCompleted

NeoplasmsPhase 2

Completed

Competition

Competitive Landscape

45 competitors in Neoplasms

#DrugCompanyPhaseTrials

Xtandi

Astellas

Phase 3

1 2

Tecentriq

Roche

Phase 3

1 3

Avastin

Roche

Phase 3

1 4

Taxol

Teva

Phase 3

1 5

Alimta

SShawn Eagle

Phase 3

1 6

Alimta

EEagle Pharmaceuticals, Inc.

Phase 3

1 7

Fludara

Sanofi

Phase 2

3 8

Cyramza

Eli Lilly

Phase 2

1 9

Gemzar

Johnson & Johnson

Phase 2

1 10

Verzenio

Eli Lilly

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2028

Phase 2Active, not recruiting

Neoplasms

NCT03967223

Clinical

Trials by Indication[1]

Neoplasms2 trials

Evaluation of Safety and Antitumor Activity of Lete-Cel (GSK3377794) in HLA-A2+ Participants With NY-ESO-1 Positive Previously Untreated Advanced (Metastatic or Unresectable) Synovial Sarcoma and Myxoid/Round Cell Liposarcoma

Completed·UUSWM, LLC (dba US WorldMeds)·Phase 2·NCT05993299·7 enrolled

Master Protocol to Assess the Safety and Antitumor Activity of Genetically Engineered NY-ESO-1-Specific (c259) T Cells, Alone or in Combination With Other Agents, in HLA-A2+ Participants With NY-ESO-1 and/or LAGE-1a Positive Solid Tumors (IGNYTE-ESO)

Active, not recruiting·UUSWM CT, LLC·Phase 2·NCT03967223·103 enrolled

Liposarcoma1 trial

Letetresgene Autoleucel Engineered T Cells in NY-ESO-1 Positive Participants With Advanced Myxoid/ Round Cell Liposarcoma

Completed· GSK logo

GSK·Phase 2·NCT02992743·23 enrolled

Non-Small Cell Lung Cancer1 trial

Letetresgene Autoleucel Engineered T Cells in NY-ESO -1 Positive Advanced Non-Small Cell Lung Cancer (NSCLC)

Completed· GSK logo

GSK·Phase 1·NCT02588612·10 enrolled

Multiple Myeloma1 trial

Letetresgene Autoleucel Engineered T Cells Alone and in Combination With Pembrolizumab in NY-ESO-1 Positive Multiple Myeloma

Terminated· GSK logo

GSK·Phase 1·NCT03168438·6 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for Letetresgene autoleucel. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Letetresgene autoleucel compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Letetresgene autoleucel. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — GSK company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Cell therapy[2]
Highest Phase: Phase 2[1]
Company: GSK

Letetresgene autoleucel

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2028

Trials by Indication[1]

Neoplasms2 trials

Liposarcoma1 trial

Non-Small Cell Lung Cancer1 trial

Multiple Myeloma1 trial

References

Drug Info

Quick Facts

Related News